openPR Logo
Press release

Nonalcoholic Steatohepatitis Therapeutics Market : creased cases of Diabetes and Obesity Stirs up the Market Demand

08-07-2018 12:31 PM CET | Health & Medicine

Press release from: Transparency Market Research 

Nonalcoholic Steatohepatitis Therapeutics Market : creased

Transparency Market Research (TMR) in its latest research report on the global nonalcoholic steatohepatitis therapeutics market has observed that players within this market both new entrants as well as those established are making equal efforts to develop an enhanced and effective treatment for NASH disease. Key players operating in the market include: Gilead Sciences, Inc., Zydus Cadila, GENFIT SA, Conatus Pharmaceuticals, Intercept Pharmaceuticals Inc., Astazeneca Plc., Immuron Ltd., Galmed Pharmaceuticals Ltd., and Tobira Therapeutics, Inc. Most of the leading biopharmaceutical companies are striving to develop novel therapeutics for NASH treatment and are carrying out clinical trials. Many of the companies are based in the U.S. and are collaborating with academic institutes and research centres so as to conduct clinical trials.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7691

According to Transparency Market Research (TMR), the global nonalcoholic steatohepatitis therapeutics market will cross US$20.27 bn by 2025. By drug type, the demand for elafibranor is highest on account of its effectiveness in reducing the effects of the NASH disease as well as the fact that it is the most advanced drug available as of now. The second most popular drug type is obeticholic acid (OCA).

North America and Europe Remain Most Attractive Regional Markets for NASH Therapeutics

By geography, the nonalcoholic steatohepatitis therapeutics market is highly attractive in regions such as North America and Europe, as these two regions are majorly affected by NASH. The growth of this market is also associated with an increasing number of people in the region suffering from obesity and diabetes. The increasing incidences of high cholesterol as well as change in lifestyle are some of the other reasons behind the continued growth of the nonalcoholic steatohepatitis therapeutics market in these regions. High growth areas for nonalcoholic steatohepatitis therapeutics market in Europe include Germany, the U.K., Spain, Italy, and France.

Enquiry for Discount on this Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=7691

Appalling Cases of Obesity among a Vast Pool of Population Worldwide Continues to Fuel Demand for Effective NASH Therapeutics

The growing incidences of NASH and nonalcoholic fatty liver diseases (NAFLD) among people worldwide is behind the rise in the demand for nonalcoholic steatohepatitis therapeutics. This demand is particularly high in the developed nations of North America and Europe. Research centres are putting in much efforts for finding an effective treatment for nonalcoholic steatohepatitis disease. The growing prevalence of obesity worldwide, including obese children have created a heightened concern and need for curing the NASH disease at an early stage and keep a check on the weight. Levels of cholesterol is also high among a vast pool of population today, especially in America and this will continue to fuel the growth of the nonalcoholic steatohepatitis therapeutics market. While no exact cure exists in the market today, the treatment for NAFLD and NASH is constantly being worked upon.

As of now, there are no therapies which have been approved and thus, there is high dependency on off label agents which offer sub-optimal efficacy and safety. There are many drugs in the later stages of the pipeline and this is expected to drive the growth prospects of the market.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nonalcoholic Steatohepatitis Therapeutics Market : creased cases of Diabetes and Obesity Stirs up the Market Demand here

News-ID: 1166365 • Views:

More Releases from Transparency Market Research 

Oligonucleotide Therapeutics Market Size, Status, Scope and Growth Prospects 2020-2030
Oligonucleotide Therapeutics Market Size, Status, Scope and Growth Prospects 202 …
Global Oligonucleotide Therapeutics Market: Overview Oligonucleotides refer to short chain DNA or RNA that are generally made by using automated synthesizers. In addition, purification of oligonucleotide is accomplished by anion exchange chromatography and it is followed by the techniques of freezing and desalting. In addition, synthesis of siRNA duplex oligonucleotide is done through an annealing step in which two purified strands of oligonucleotide are brought closer together in an equimolar ratio.
Seasonal Affective Disorder Therapeutics Market Size, Status, Scope and Growth Prospects 2020-2030
Seasonal Affective Disorder Therapeutics Market Size, Status, Scope and Growth P …
Global Seasonal Affective Disorder Therapeutics Market: Overview From 2020 to 2030, the global seasonal affective disorder is set to witness new profitable avenues. It is set to chart growth at a sturdy rate, compounded annually, with massive contributions coming from the North American region. On the other hand, Asia Pacific is anticipated to grow at an impressive CAGR. Transparency Market Research notes that various factors are contributing towards the projected growth. These
Esthetic Lasers and Energy Devices Market set to witness surge in demand over the forecast period of 2017 - 2025
Esthetic Lasers and Energy Devices Market set to witness surge in demand over th …
In the past few years, the cosmetic industry has found new bioactive and high potency ingredients, which offer noticeable skin benefits to consumers. Various technological advancements in the esthetic industry, increase in disposable income, surge in awareness about skin rejuvenation & appearance are the major factors driving demand for esthetic procedures in developed as well as developing markets. The trend of adoption of innovative and advanced surgical devices in the
Image Guided Surgery Devices Market Analysis and Research Report by Experts 2025
Image Guided Surgery Devices Market Analysis and Research Report by Experts 2025
The global image guided surgery devices market is directly reliant on the development of healthcare across various regional longitudes of the world. As the healthcare industry make rapid advancements across a number of its sub-domains, the market for global image guided surgery devices would see the entry of new players into the market. The competition is expected to intensify in the coming years and wreak the need for proper strategizing

All 5 Releases


More Releases for NASH

NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
IQ4I Research published “Non-alcoholic steatohepataitis (NASH) Pipeline Analys …
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and
04-07-2017 | Arts & Culture
Memphia PR
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will